<?xml version="1.0"?>
<rss version="2.0">
<channel>
<title>EIN News: Benelux Pharmaceuticals News</title>
<link>http://www.einnews.com/benelux/newsfeed-benelux-pharmaceuticals</link><description>Constantly updated news and information about world affairs.</description><item>
<title>ALTADIS : IMPERIAL TOBACCO GROUP PLC INTERIM MANAGEMENT STATEMENT</title>
<link>http://www.einnews.com/news.php?wid=180019773</link>
<pubDate>24 Jul 2008 09:04 GMT</pubDate>
<description>
...  in many markets including France, Belgium, The Netherlands and Greece with the benefit of strong  ...  travel retail declines impacted our performance in Belgium and Luxembourg. In the USA, we estimate that the  ...
</description>
</item><item>
<title>A whole world in their hands as Chinese warm to Chelsea&apos;s masterplan</title>
<link>http://www.einnews.com/news.php?wid=179968475</link>
<pubDate>24 Jul 2008 01:37 GMT</pubDate>
<description>
...  last night as they took on Guangzhou Pharmaceutical. The previous evening, around 100 highly excited  ...  game), Austria (1 game), Germany (1 game), Holland (2 games) Aston Villa Switzerland (2games), Denmark  ...  Switzerland (1 game), USA (2 games) Hull Belgium (1 game), Scotland (1 game) Liverpool Switzerland  ...
</description>
</item><item>
<title>Benelux shares close higher; Dexia, Fortis head gainers UPDATE</title>
<link>http://www.einnews.com/news.php?wid=179923571</link>
<pubDate>23 Jul 2008 19:53 GMT</pubDate>
<description>
... Benelux shares close higher; Dexia, Fortis head gainers  ...  to buy a further 25.5 percent in Belgium&apos;s second largest power generator, SPE, from Gaz  ...  upgraded its full-year EBITDA guidance for the Netherlands to &apos;flat&apos; versus 2007 from a maximum  ...
</description>
</item><item>
<title>Dyax Corp. Q2 2008 Earnings Call Transcript</title>
<link>http://www.einnews.com/news.php?wid=179914489</link>
<pubDate>23 Jul 2008 18:57 GMT</pubDate>
<description>
...  Gustav Christensen, Executive Vice President and Chief Business Officer; Ivana Magovcevic-Liebisch, EVP and General Counsel;  ...  in relationship to the closure of the Belgium research facility. Our total revenue for the  ...  half of 2008, including Sanofi-aventis and Cubist Pharmaceuticals, as well as the exclusive negotiation agreement  ...
</description>
</item><item>
<title>Benelux shares close higher; Dexia, Fortis head gainers</title>
<link>http://www.einnews.com/news.php?wid=179908114</link>
<pubDate>23 Jul 2008 18:17 GMT</pubDate>
<description>
... Benelux shares close higher; Dexia, Fortis head gainers  ...  to buy a further 25.5 percent in Belgium&apos;s second largest power generator, SPE, from Gaz  ...  upgraded its full-year EBITDA guidance for the Netherlands to &apos;flat&apos; versus 2007 from a maximum  ...
</description>
</item><item>
<title>Trigen Appoints Dr. Ayad Abdul-Ahad as Chief Executive Officer and Dr. Norbert Bender as Chief Medical Officer</title>
<link>http://www.einnews.com/news.php?wid=179891524</link>
<pubDate>23 Jul 2008 16:18 GMT</pubDate>
<description>
...  natalizumab (Tysabri) and Avonex, in addition to business development and medical marketing. Prior to this,  ...  Clinical Developments &amp; Regulatory Affairs, SmithKline Beecham, Belgium, and Therapeutic Director Immunology &amp; Oncology, Serono,  ...  brings 15 years of experience in big pharmaceutical companies (Head of Clinical Research - Cardiovascular  ...
</description>
</item><item>
<title>Merck Serono Receives European Approval for Broader Usage of Erbitux in Metastatic Colorectal Cancer including 1st-Line Treatment</title>
<link>http://www.einnews.com/news.php?wid=179876733</link>
<pubDate>23 Jul 2008 14:52 GMT</pubDate>
<description>
...  at the University Hospital Gasthuisberg in Leuven, Belgium. &amp;ldquo;We are excited by the data supporting  ...  Serono is the division for innovative prescription pharmaceuticals of Merck, a global pharmaceutical and chemical  ...  with unmet medical needs. Its North American business operates in the United States and Canada  ...
</description>
</item><item>
<title>Irish Merchandise Exports increased 7% in May</title>
<link>http://www.einnews.com/news.php?wid=179872252</link>
<pubDate>23 Jul 2008 14:17 GMT</pubDate>
<description>
...  Chemical materials increased by 47%, Medical and pharmaceutical products by 8%, Electrical machinery by 5%  ...  Goods to Switzerland decreased by 35%, the Netherlands by 18%, Belgium by 2%, Germany by 9% and the  ...
</description>
</item><item>
<title>UPDATE 1-Dyax posts wider Q2 loss</title>
<link>http://www.einnews.com/news.php?wid=179869787</link>
<pubDate>23 Jul 2008 13:55 GMT</pubDate>
<description>
... July 23 (Reuters) - Dyax Corp (DYAX.O: ) posted a wider quarterly loss,  ...  charge related to the closing of its Belgium research plant, but for the second straight  ...  helped by its licensing agreement with Cubist Pharmaceuticals Inc (CBST.O: Analysts on average expected a  ...
</description>
</item><item>
<title>Nielsen and Wolters Kluwer Health Form Alliance to Measure Healthcare Landscape</title>
<link>http://www.einnews.com/news.php?wid=179864095</link>
<pubDate>23 Jul 2008 13:30 GMT</pubDate>
<description>
...  with Wolters Kluwer Health&apos;s expertise in prescribed pharmaceuticals -- providing new insight and metrics for  ...  inform and optimize their strategies. &quot;The healthcare industry including manufacturers and media companies are confronted  ...  Wolters Kluwer is headquartered in Amsterdam, the Netherlands. Visit for information about our market positions,  ...
</description>
</item><item>
<title>Genzyme Reports Strong Second-Quarter Growth</title>
<link>http://www.einnews.com/news.php?wid=179857680</link>
<pubDate>23 Jul 2008 12:50 GMT</pubDate>
<description>
...  made a $175 million payment to Isis Pharmaceuticals to secure the rights to mipomersen, significantly  ...  of 2009. Approval of 4000L-scale production in Belgium will be necessary to meet the anticipated  ...  C-section procedures. Second-quarter revenue for the Genetics business increased 7 percent to $78.5 million from  ...
</description>
</item><item>
<title>Dyax Corp. Announces Second Quarter 2008 Financial Results</title>
<link>http://www.einnews.com/news.php?wid=179850173</link>
<pubDate>23 Jul 2008 11:51 GMT</pubDate>
<description>
...  2008, Dyax moved to close its Liege, Belgium research facility and recorded a related restructuring  ...  Advances have included the partnership with Cubist Pharmaceuticals for the development and commercialization of DX-88  ...  forecasts and projections for Dyax and the industry and markets in which Dyax competes. The  ...
</description>
</item><item>
<title>Galapagos transfers predictive drug discovery databa...</title>
<link>http://www.einnews.com/news.php?wid=179849999</link>
<pubDate>23 Jul 2008 11:51 GMT</pubDate>
<description>
...  makes software publicly available to researchers MECHELEN, Belgium  Galapagos NV announces the transfer of  ...  of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery and  ...  condition, performance or achievements of Galapagos, or industry results, to be materially different from any  ...
</description>
</item><item>
<title>Schleck maintains lead as toughest stage looms</title>
<link>http://www.einnews.com/news.php?wid=179837313</link>
<pubDate>23 Jul 2008 09:55 GMT</pubDate>
<description>
... JAUSIERS, France  Frank Schleck of Luxembourg kept the yellow jersey in the Tour  ...  the French anti-doping agency. Fahey said Roche Pharmaceuticals placed a molecule in its product CERA  ...  cooperation occurred between WADA and the pharmaceutical company Roche Pharmaceuticals,&quot; Fahey said, &quot;so that there  ...
</description>
</item><item>
<title>Euroshares outlook - higher after Dow gains; oil back below $129</title>
<link>http://www.einnews.com/news.php?wid=179817746</link>
<pubDate>23 Jul 2008 07:15 GMT</pubDate>
<description>
...  after another drop in oil prices encouraged investors to set aside disappointment from Wachovia and  ...  raised its 2008 EBITDA guidance for the Netherlands. The group also said it will pay  ...  up from 2.7 percent a year earlier. Pharmaceuticals could be in the spotlight with GlaxoSmithKline  ...
</description>
</item></channel>
</rss>
